The safety label of the top-selling oral multiple sclerosis (MA) drug Tecfidera has been updated to include new warnings of potential liver injury that could require hospitalization, drug maker Biogen Inc. reported. A total of 14 cases of liver injury were reported out of about 230,000 patients treated with the MS drug. Symptoms included significant elevations above normal of serum aminotransferases and bilirubin. Signs of liver injury resolved in patients after treatment with Tecfidera was discontinued, and none resulted in liver failure, liver transplant, or death. The new warning is listed under the Warnings and Precautions section under the prescribing information ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.